COAG (Hemab Therapeutics Holdings, Inc. Common Stock) Stock Analysis - Politician Trades
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is a publicly traded the market company. As of May 21, 2026, COAG trades at $26.47 with a market cap of $1.27B and a P/E ratio of 0.00. COAG moved +2.40% today. Year to date, COAG is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $23.00 to $36.61. Rallies surfaces COAG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded COAG stock?
Rallies tracks politician and congressional stock disclosures for COAG, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
RA CAPITAL MANAGEMENT, L.P. bought 6.39K (~$159.04K) on May 12, 2026.
RA CAPITAL MANAGEMENT, L.P. bought 14.15K (~$346.23K) on May 11, 2026.
RA CAPITAL MANAGEMENT, L.P. bought 25.72K (~$643.00K) on May 11, 2026.
COAG Analyst Consensus
COAG analyst coverage data. Average price target: $0.00.
Common questions about COAG
Which politicians traded COAG stock?
Rallies tracks politician and congressional stock disclosures for COAG, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Does Rallies track congressional trades in COAG?
Yes. Rallies tracks politician and congressional stock disclosures for COAG, including reported purchases, sales, dates, owners, and trade amounts when available.
Is COAG research on Rallies investment advice?
No. Rallies provides research, data, and educational context for COAG. It does not provide personalized investment advice.